Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | CLK1 | P49759 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989250 | 1.00 | LRRK2 (0.50) | LRRK2CHEK1PIK3CAMTORCLK1 | |
| Zinc Ion SCHEMBL30758890 | 0.95 | LRRK2 (0.46) | LRRK2CHEK1PIK3CAMTORCLK1 | |
| SCHEMBL12269859 | 0.75 | GRM5 (0.41) | PIK3CAMTOR | |
| SCHEMBL12269780 | 0.75 | PIK3CA (0.60) | LRRK2PIK3CAMTORAXLAURKA | |
| SCHEMBL174642 | 0.72 | PDPK1 (0.48) | LRRK2CHEK1CDK5CDK5R1CLK4 | |
| SCHEMBL30631993 | 0.72 | PDPK1 (0.48) | LRRK2CHEK1CDK5CDK5R1CLK4 | |
| SCHEMBL1495296 | 0.72 | PDPK1 (0.48) | LRRK2CHEK1CDK5CDK5R1CLK4 | |
| SCHEMBL29723169 | 0.71 | MAPK1 (0.32) | LRRK2CDK5CDK5R1KDM4EALDH1A1 | |
| SCHEMBL1593049 | 0.71 | AXL (0.50) | LRRK2PIK3CAMTORAXLAURKA | |
| SCHEMBL1290531 | 0.71 | KDM4E (0.52) | LRRK2ERBB2AURKAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| CN-117924280-B | Substituted thienyl-5-fluoro-1H-pyrazolopyridine compound and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2024-07-12 | — | — | CN | disclosed |
| CN-117924280-A | Substituted thienyl-5-fluoro-1H-pyrazolopyridine compound and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2024-04-26 | — | — | CN | disclosed |
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-110267658-B | Treatment of CNS disorders with sGC stimulators | 帝善多制药公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2008147815-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008147822-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| EP-1906965-A2 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007128454-A1 | 3-TETRAZOLYL INDAZOLES, 3-TETRAZOLYL PYRAZOLOPYRIDINES, AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007128454-A1 | 3-TETRAZOLYL INDAZOLES, 3-TETRAZOLYL PYRAZOLOPYRIDINES, AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007002293-A2 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | LRRK2 4834/4885CHEK1 2417/4885PIK3CA 4034/4885 |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CCR1, CCR3, CCR4 | LRRK2 4542/4885CHEK1 1454/4885PIK3CA 2568/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | LRRK2 640/4885CHEK1 2001/4885PIK3CA 2631/4885 |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | LRRK2 598/4885CHEK1 3485/4885PIK3CA 3332/4885 |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | PDE9A, PDE2A, GUCY1A2 | LRRK2 254/4885CHEK1 3516/4885PIK3CA 3055/4885 |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | LRRK2 598/4885CHEK1 3485/4885PIK3CA 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.